Sign in to view content

Economic Benefit of Higher Durability Anti-VEGF Agents in the Treatment of Neovascular Macular Degeneration

Sabin Dang, MD

Video
Published 2023

Related

Safety and Efficacy of Switching to Biosimilar Ranibizumab in Eyes Initially Treated With Reference Ranibizumab for nAMD, DME, or RVO
Nikhil K Bommakanti, MD
Annual Meeting Talks
2024
Long-Term Efficacy and Safety of the Port Delivery System With Ranibizumab in Patients With nAMD: Results of the Portal 5-year Subgroup Analysis
David J Massop, MD
Annual Meeting Talks
2023
Intermittent to Continuous Therapy for Diabetic Macular Edema leads to Reduction in Treatment Frequency and Reduced Retinal Thickness Fluctuations
Seenu M. Hariprasad, MD
On Demand Cases, Courses, and Papers
2019

Category: Socioeconomics

See more